Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  207.92
-2.72 (-1.29%)
AAPL  272.95
-1.28 (-0.47%)
AMD  203.68
-7.18 (-3.41%)
BAC  52.30
+0.61 (1.18%)
GOOG  307.15
-5.88 (-1.88%)
META  657.01
+3.32 (0.51%)
MSFT  401.72
+1.12 (0.28%)
NVDA  184.89
-10.67 (-5.46%)
ORCL  150.31
+2.42 (1.64%)
TSLA  408.58
-8.82 (-2.11%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.